Abstract
Siramesine is a sigma2 opioid agonist under development by H Lundbeck as a potential treatment for anxiety 11678721. In March 1998, the compound was licensed to Forest Laboratories under a strategic alliance [282593]. In August 2000, siramesine entered phase II trials [378814]. Phase III trials are expected to take place in 2002 [387270]. A series of compounds have been synthesized by Lundbeck, the most potent of which may serve as a backup compound [179036].
MeSH terms
-
Animals
-
Anti-Anxiety Agents / pharmacokinetics
-
Anti-Anxiety Agents / therapeutic use*
-
Anti-Anxiety Agents / toxicity
-
Anxiety / drug therapy*
-
Anxiety / psychology
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Female
-
Humans
-
Indoles / pharmacology
-
Indoles / therapeutic use*
-
Indoles / toxicity
-
Male
-
Receptors, sigma / agonists*
-
Spiro Compounds / pharmacology
-
Spiro Compounds / therapeutic use*
-
Spiro Compounds / toxicity
-
Structure-Activity Relationship
Substances
-
Anti-Anxiety Agents
-
Indoles
-
Lu 28-179
-
Receptors, sigma
-
Spiro Compounds